GlassScriptPhysician profile
Yulander B Gailey
NPI 1265735922
$963.39
in general payments reported to CMS, 2019-2025
19 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.52 · 2022: $97.08 · 2023: $230 · 2024: $381 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $165.29 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $116.39 | 2023-2024 | Breztri, Farxiga |
| Vertex Pharmaceuticals Incorporated | $88.35 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $76.82 | 2025 | |
| Viiv Healthcare Company | $75.80 | 2025 | Apretude |
| Glaxosmithkline, LLC. | $63.18 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $46.86 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $44.12 | 2024 | Intellis Adaptivestim |
| Dexcom, INC. | $42.62 | 2023-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $38.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.52 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.77 | 2024 | Jardiance |
| Pfizer INC. | $29.63 | 2023-2024 | |
| Averitas Pharma INC. | $24.04 | 2024 | Qutenza |
| Ucb, INC. | $24.02 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $19.00 | 2022 | |
| Astellas Pharma US INC | $17.64 | 2024 | Veozah |
| Shield Therapeutics INC | $14.18 | 2024 | |
| Phathom Pharmaceuticals, INC. | $13.54 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yulander Gailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.